Cargando…

Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs

The recently conducted ADAURA trial concludes daily dosing of adjuvant osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), improves disease-free survival with stage IB/II/IIIA EGFR -mutated non-small cell lung cancer patients in comparison to placebo. We have developed a preclinica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Butle, Ashwin, Joshi, Asim, Noronha, Vanita, Prabhash, Kumar, Dutt, Amit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2021
Materias:	Spotlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236545/ https://www.ncbi.nlm.nih.gov/pubmed/33993094 http://dx.doi.org/10.1016/j.tranon.2021.101111

Ejemplares similares

Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation
por: Joshi, Asim, et al.
Publicado: (2022)

How the vacuole ESCRTs its own proteins to their final destination
por: Henne, W. Mike
Publicado: (2021)

Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2017)

EGFR Mutations in Indian Lung Cancer Patients: Clinical Correlation and Outcome to EGFR Targeted Therapy
por: Noronha, Vanita, et al.
Publicado: (2013)

Frequency of EGFR Mutations in 907 Lung Adenocarcioma Patients of Indian Ethnicity
por: Chougule, Anuradha, et al.
Publicado: (2013)

Air pollution, EGFR mutation, and cancer initiation
por: Han, Si-Chong, et al.
Publicado: (2023)

Confusion worse confounded
por: Noronha, Vanita, et al.
Publicado: (2013)

A decoy mutant ACE2 designed to reduce COVID-19
por: Maishan, Mazharul, et al.
Publicado: (2022)

GOLPH3 keeps the Golgi residents at home
por: Lowe, Martin
Publicado: (2021)

Marlies Wijsenbeek—advocating home monitoring in ILD
por: Kirby, Tony
Publicado: (2023)

The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients
por: Noronha, Vanita, et al.
Publicado: (2014)

Truly epigenetic: A centromere finds a “neo” home
por: Carty, Ben L., et al.
Publicado: (2021)

Weekly paclitaxel as metronomic palliative chemotherapy in small cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2016)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
por: Lee, Jiyun, et al.
Publicado: (2022)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?
por: Joshi, Amit, et al.
Publicado: (2017)

Comparison of postoperative complications in advanced head and neck cancer patients receiving neoadjuvant chemotherapy followed by surgery versus surgery alone
por: Joshi, Poonam, et al.
Publicado: (2015)

Successful Treatment of EGFR-Mutant Synchronous SCLC and Lung Adenocarcinoma With Osimertinib
por: Batra, Ullas, et al.
Publicado: (2020)

Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2019)

Thyroid cancer in Gardner’s syndrome: Case report and review of literature
por: Punatar, Sachin B, et al.
Publicado: (2012)

Geriatric oncology: The need of the hour
por: Joshi, Amit, et al.
Publicado: (2013)

A systematic approach to diagnosis of cystic brain lesions
por: Sharma, Vibhor, et al.
Publicado: (2013)

Crizotinib: A comprehensive review
por: Sahu, Arvind, et al.
Publicado: (2013)

An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast–ovarian cancer syndrome
por: Talreja, Vikas T., et al.
Publicado: (2020)

Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer
por: Choughule, A, et al.
Publicado: (2014)

EGFR‐mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib
por: Hara, Reina, et al.
Publicado: (2021)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
por: Ye, Qiuyue, et al.
Publicado: (2023)

Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
por: Kate, Shruti, et al.
Publicado: (2019)

Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once‐a‐week versus once‐every‐3‐weeks cisplatin
por: Menon, Nandini S., et al.
Publicado: (2022)

Carcinomatous meningitis in non-small cell lung cancer: Palliation with intrathecal treatment
por: Kumar, D. Santhosh, et al.
Publicado: (2014)

Lung cancer in the Indian subcontinent
por: Noronha, Vanita, et al.
Publicado: (2016)

Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
por: Talreja, Vikas T., et al.
Publicado: (2020)

A new system for multiplexed mosaic analysis of gene function in the mouse
por: Cai, Hongchen, et al.
Publicado: (2022)

Provision of holistic care after severe COVID-19 pneumonia: anticipating clinical need and managing resources
por: D'Cruz, Rebecca F, et al.
Publicado: (2020)

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
por: Roper, Nitin, et al.
Publicado: (2020)

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
por: Ortega-Franco, Ana, et al.
Publicado: (2022)

Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer
por: Veldore, Vidya H, et al.
Publicado: (2018)

Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment
por: Noronha, Vanita, et al.
Publicado: (2017)

Resistant metastatic penile carcinoma and response to biochemotherapy with paclitaxel and epidermal growth factor receptor monoclonal antibody, nimotuzumab
por: Pandey, Avinash, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8vdkbrketajevg08rqfk54jfrg